首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support is reappraisal of the current United Network for Organ Sharing thoracic organ allocation policy justified?
【24h】

Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support is reappraisal of the current United Network for Organ Sharing thoracic organ allocation policy justified?

机译:心脏移植候选人的发病率和死亡率支持机械循环支持,是目前联合网络的机构共享胸风器官分配政策的恢复?

获取原文
获取原文并翻译 | 示例
           

摘要

Background:-Survival of patients on left ventricular assist devices (LVADs) has improved. We examined the differences in risk of adverse outcomes between LVAD-supported and medically managed candidates on the heart transplant waiting list. Methods and Results:-We analyzed mortality and morbidity in 33 073 heart transplant candidates registered on the United Network for Organ Sharing (UNOS) waiting list between 1999 and 2011. Five groups were selected: patients without LVADs in urgency status 1A, 1B, and 2; patients with pulsatile-flow LVADs; and patients with continuous-flow LVADs. Outcomes in patients requiring biventricular assist devices, total artificial heart, and temporary VADs were also analyzed. Two eras were defined on the basis of the approval date of the first continuous-flow LVAD for bridge to transplantation in the United States (2008). Mortality was lower in the current compared with the first era (2.1%/mo versus 2.9%/mo; P<0.0001). In the first era, mortality of pulsatile-flow LVAD patients was higher than in status 2 (hazard ratio [HR], 2.15; P<0.0001) and similar to that in status 1B patients (HR, 1.04; P=0.61). In the current era, patients with continuous-flow LVADs had mortality similar to that of status 2 (HR, 0.80; P=0.12) and lower mortality compared with status 1A and 1B patients (HR, 0.24 and 0.47; P<0.0001 for both comparisons). However, status upgrade for LVAD-related complications occurred frequently (28%) and increased the mortality risk (HR, 1.75; P=0.001). Mortality was highest in patients with biventricular assist devices (HR, 5.00; P<0.0001) and temporary VADs (HR, 7.72; P<0.0001). Conclusions:-Mortality and morbidity on the heart transplant waiting list have decreased. Candidates supported with contemporary continuous-flow LVADs have favorable waiting list outcomes; however, they worsen significantly once a serious LVAD-related complication occurs. Transplant candidates requiring temporary and biventricular support have the highest risk of adverse outcomes. These results may help to guide optimal allocation of donor hearts.
机译:背景:左心室辅助装置(LVAD)上的患者的患者改善了。我们在心脏移植等候名单上审查了LVAD支持和医学管理的候选人之间不利结果的风险的差异。方法和结果: - 我们在1999年和2011年间登录的33 073年心脏移植候选人中分析了23个073心脏移植候选人,以便于1999年至2011年间等待名单。选择了五组:没有LVAD的患者紧急状态1a,1b和2;脉动流动LVAD的患者;和患者连续流动的LVAD。还分析了需要五个辅助装置,总人造心脏和临时VAD的患者的结果。根据美国第一次连续流动LVAD的批准日期来定义两种时代,以便在美国进行移植(2008)。与第一个时代相比,当前死亡率降低(2.1%/ Mo对2.9%/ mo; p <0.0001)。在第一个时代,脉动流动LVAD患者的死亡率高于状态2(危害比[HR],2.15; P <0.0001),并且类似于状态1B患者(HR,1.04; P = 0.61)。在目前的时代,连续流动LVAD患者的死亡率与状态2(HR,0.80; P = 0.12)的死亡率相比,与状态1A和1B患者(HR,0.24和0.47; P <0.000)相比,降低死亡率比较)。但是,频繁发生与LVAD相关的并发症的状态升级(28%)并增加死亡率风险(HR,1.75; P = 0.001)。双心辅助装置(HR,5.00; P <0.0001)和临时VAD(HR,7.72; P <0.0001)患者中死亡率最高。结论:心脏移植等候名单上的性能和发病率降低。当代连续流动LVAD的候选人有利的等候名单结果;然而,一旦发生严重的LVAD相关的并发症,它们会显着恶化。需要临时和五十次支持的移植候选者具有最高的不良结果的风险。这些结果可能有助于指导捐赠者心灵的最佳分配。

著录项

  • 来源
  • 作者单位

    U.T.A.H. Cardiac Transplant Program University of Utah Health Sciences Center Salt Lake City UT;

    U.T.A.H. Cardiac Transplant Program University of Utah Health Sciences Center Salt Lake City UT;

    U.T.A.H. Cardiac Transplant Program Intermountain Medical Center Salt Lake City UT United States;

    U.T.A.H. Cardiac Transplant Program University of Utah Health Sciences Center Salt Lake City UT;

    U.T.A.H. Cardiac Transplant Program University of Utah Health Sciences Center Salt Lake City UT;

    U.T.A.H. Cardiac Transplant Program Primary Children's Medical Center Salt Lake City UT United;

    U.T.A.H. Cardiac Transplant Program Intermountain Medical Center Salt Lake City UT United States;

    U.T.A.H. Cardiac Transplant Program Intermountain Medical Center Salt Lake City UT United States;

    U.T.A.H. Cardiac Transplant Program University of Utah Health Sciences Center Salt Lake City UT;

    U.T.A.H. Cardiac Transplant Program University of Utah Health Sciences Center Salt Lake City UT;

    U.T.A.H. Cardiac Transplant Program University of Utah Health Sciences Center Salt Lake City UT;

    U.T.A.H. Cardiac Transplant Program University of Utah Health Sciences Center Salt Lake City UT;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 心脏、血管(循环系)疾病;
  • 关键词

    Heart-assist devices; Mortality; Outcome assessment; Transplantation;

    机译:心脏辅助设备;死亡率;结果评估;移植;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号